Talquetamab monotherapy linked to 51% any-grade infection rate in relapsed/refractory myeloma
New data shows infection risks for patients on talquetamab
This systematic review and meta-analysis assessed infection risk with talquetamab in relapsed/refractory multiple myeloma. Pooled rates were…
Patients with relapsed or refractory multiple myeloma may face significant infection risks when treated with the drug talquetamab.
Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence
Teclistamab linked to higher infection rates in some patients
This meta-analysis of 714 patients evaluates the incidence of infections in relapsed/refractory multiple myeloma treated with teclistamab.
New data shows that patients using teclistamab for multiple myeloma may face a significant risk of developing various types of infections.
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …